SUBSYS

Peak

fentanyl

NDASUBLINGUALSPRAY
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Clinical Trials (5)

NCT06953453Phase 1Recruiting

A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors

Started Sep 2025
100 enrolled
Cancer
NCT05531422Phase 2Completed

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Started Oct 2021
60 enrolled
Breakthrough Cancer Pain
NCT04713189Phase 1/2Unknown

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain

Started Mar 2021
96 enrolled
Breakthrough Cancer Pain
NCT04136548Phase 1/2Completed

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Fentanyl

Started Jun 2019
41 enrolled
Healthy
NCT03869346N/AUnknown

Impact of CYP3A4*1G Polymorphism on Non-analgesic Effects of Fentanyl in Chinese Han Patients

Started Mar 2019
200 enrolled
Fentanyl

Loss of Exclusivity

LOE Date
Apr 27, 2030
50 months away
Patent Expiry
Apr 27, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
9642844
Jan 25, 2027
Product
10610523
Jan 25, 2027
Product
9642797
Jan 25, 2027
Product
U-55
10016403
Jan 25, 2027
Product
8835459
Jan 25, 2027
Product